Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 335 participants.
Also called NCT01235351
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 335 participants
- Registry
-
NCT01235351
-
- Other papers using this trial's data
- Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial
- Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
- Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01235351. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2019-11-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56
- Acronym
- ELEVATE
- Condition
- Myocardial Infarction
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- The TIMI Study Group
- Collaborator
- Bristol-Myers Squibb
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct01235351- Content hash
24eaf4da389ac0b1c04f8d9b2e0d7b6c41c7ab1cb9b948fd81dded6e2bc78552